source
- FDA delays decision on Savara's rare lung disease therapy, pushing back deadlineThe FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…
- Ailux appoints former Johnson & Johnson executive Lloyd Miller as chief medical officerAilux announced the hiring of Lloyd Miller as its new chief medical officer. Miller comes from Johnson & Johnson where he served as senior vice president and global head of translational science &…